Member Access Hub &
Clinical FAQ Library

Yes. Center for Men’s Health Rhode Island accepts a wide range of commercial health insurance plans for clinical consultations, diagnostic evaluations, and laboratory testing. Because coverage criteria and prior-authorization rules vary significantly across individual policies, we recommend calling the member services number on the back of your insurance card to confirm in-network status, and our Providence administrative team will gladly verify your specific benefits prior to your appointment.

Absolutely. Many patients prefer not to route sensitive sexual health, STI, or hormone evaluations through a shared family or employer-sponsored insurance plan, while others pursue specialized modalities (such as compounded intracavernosal medications or investigational shockwave therapy) that fall outside commercial payer coverage. We offer transparent, upfront self-pay pricing with zero forced multi-cycle contracts or hidden fees.

Commercial online “men’s clinics” often rely on automated questionnaires, truncated fingerstick blood tests, and one-size-fits-all subscription shipments without physical examination or differential diagnosis. At CMH-RI, you receive unhurried, in-person medical care at our Providence facility led by experienced clinical leadership—combining confirmatory venipuncture diagnostics, cardiovascular and prostate safety surveillance, and individualized multimodal care.

Please bring a valid government-issued photo ID, your current commercial insurance card (if utilizing insurance), an accurate list of your current prescription medications and supplements, and copies of any laboratory results or relevant medical records completed within the past 6 to 12 months. Completing your new-patient enrollment inside our eClinicalWorks portal before arrival will streamline your check-in.

Endogenous testosterone secretion follows a pronounced circadian rhythm driven by pulsatile GnRH and LH signaling, peaking between 7:00 AM and 10:00 AM and declining significantly by afternoon. Furthermore, acute illness, poor sleep, or nutritional shifts can temporarily suppress serum levels. In strict accordance with American Urological Association (AUA) and Endocrine Society guidelines, a clinical diagnosis of male hypogonadism requires persistent clinical symptoms paired with two separate early-morning venipuncture measurements confirming biochemical deficiency.

Roughly 97% to 99% of circulating testosterone is bound to Sex Hormone-Binding Globulin (SHBG) and albumin, leaving only 1% to 3% biologically active as Free Testosterone. Men with elevated SHBG may exhibit a “normal” Total Testosterone reading while experiencing classic androgen deficiency due to low bioavailable hormone. Evaluating gonadotropins (LH and FSH) also allows our clinician to distinguish primary testicular dysfunction from secondary hypothalamic-pituitary suppression before designing a treatment plan.

Exogenous testosterone triggers negative feedback along the hypothalamic-pituitary-gonadal (HPG) axis, suppressing pituitary secretion of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). This diminishes intratesticular testosterone and can severely reduce or halt spermatogenesis (sperm production). Men who are actively trying to conceive or wish to preserve near-term fertility are counseled thoroughly on alternative endocrine strategies prior to initiating therapy.

Longitudinal safety surveillance is a cornerstone of our practice. We conduct scheduled clinical and laboratory evaluations monitoring serum testosterone levels, Complete Blood Count (CBC) to watch for androgen-induced erythrocytosis (elevated hematocrit/hemoglobin), Prostate-Specific Antigen (PSA), Estradiol, lipid profiles, hepatic/renal function, blood pressure, and lower urinary tract symptoms.

Oral PDE5 inhibitors (such as Sildenafil and Tadalafil) require intact cavernosal nerve signaling and endogenous nitric oxide release to amplify smooth muscle relaxation. In men with moderate-to-severe endothelial dysfunction, diabetes, or post-prostatectomy nerve trauma, oral agents frequently prove insufficient. Intracavernosal injection (ICI) therapies deliver vasoactive agents directly into the corpus cavernosum, bypassing neural pathways to produce localized arterial dilation within 5 to 15 minutes—supported by in-office clinician titration and priapism safety training.

Low-intensity extracorporeal shockwave therapy (Li-ESWT / rESWT) is offered as a non-surgical acoustic pulse option for select men with mild-to-moderate vasculogenic erectile dysfunction or Peyronie’s disease discomfort. In the United States, acoustic wave therapy is not FDA-cleared or FDA-approved for the treatment of erectile dysfunction, BPH, or Peyronie’s disease; per AUA and SMSNA guidelines, its use for these indications is classified as investigational and is provided on a transparent self-pay basis following informed clinical consent.

Peyronie’s disease involves localized fibrous collagen plaques developing within the tunica albuginea of the penis, resulting in curvature, indentation, painful erections, and often co-occurring erectile difficulty. In alignment with the AUA Peyronie’s Disease Guideline, our evaluation distinguishes between the acute active inflammatory phase (where plaque remodeling is still evolving) and the chronic stable phase, allowing us to recommend appropriate conservative traction, medical, or surgical urology referral pathways.

Yes. Lower urinary tract symptoms attributed to Benign Prostatic Hyperplasia (BPH) and erectile dysfunction frequently coexist and share underlying smooth-muscle and microvascular pathways. During your evaluation, we quantify symptom severity using the International Prostate Symptom Score (IPSS) and select medical therapies—such as daily PDE5 inhibition or carefully chosen alpha-1 adrenergic antagonists—with an explicit focus on preserving ejaculatory and erectile function.

Every urogenital pathogen has a distinct biological “window period” between exposure and reliable laboratory detection. High-sensitivity Nucleic Acid Amplification Tests (NAAT/PCR) for Chlamydia trachomatis and Neisseria gonorrhoeae are typically informative 5 to 14 days post-exposure, whereas Mycoplasma genitalium and 4th-generation HIV-1/2 Ag/Ab assays are most reliable between 14 and 28 days, and Syphilis serology between 3 and 6 weeks. If you have active symptoms or a known partner exposure, schedule an evaluation immediately for clinical assessment and baseline testing.

Standard internet email is not encrypted end-to-end for Protected Health Information (PHI). To safeguard your confidentiality under HIPAA, general website inquiry forms and standard email are restricted to administrative scheduling questions. All clinical communications, laboratory panels, and prescription requests are handled exclusively inside our encrypted eClinicalWorks and healow Patient Portal.